Daxor Corporation · NASDAQ:DXR
Daxor — Investor Presentation (January 2026)
37 slides from Daxor's investor presentation, Jan 23, 2026
Slide 1: Daxor Presentation January 2026
DAXOR THE BLOOD VOLUME COM Presentation January 2026 Nasdaq: DXR
Slide 2: Disclaimer
Disclaimer The content of this document is for information purposes only. It contains confidential information pertaining to the business and affairs of Daxor Corporation (along with its subsidiaries and affiliates, the "Company", "we", "us", and “our"). It does not constitute an offer to sell or th
Slide 3: Who We Are & Opportunity
Who We Are & Opportunity
Slide 4: Mission
Mission Advance / healthcare by . enabling Vision optimal fluid Optimal blood management with blood volume analysis. volume for all. ‘HE BON WME CAPT
Slide 5: Daxor Is the Global Leader in Blood Volume Measurement Technology
Daxor Is the Global Leader in Blood Volume Measurement Technology DAX@R Daxor operates a 20,000 SF state- of-the-art R&D and production facility in Oak Ridge, TN. This vertically integrated infrastructure can produce 400+ BVA analyzers and 200,000 test kits annually.
Slide 6: Daxor is a Radiopharmaceutical Company Selling Volumex Test Kits
Daxor is a Radiopharmaceutical Company Selling Volumex® Test Kits Used With Our BVA Companion Analyzer Every BVA test consumes a test kit, ensuring a predictable and scalable recurring income stream. BVA Companion Analyzer Volumex Radiopharmaceutical ‘HENOIOMUNE CNT
Slide 7: Blood Volume Management: The Cornerstone of Care for Acute and Chronic Conditions
Blood Volume Management: The Cornerstone of Care for Acute and Chronic Conditions in Both Inpatient and Outpatient Settings Examples ‘ ¢ & e: & ‘Oy ‘ay Heart Critical sepsis Syncope Surgical ARDS Failure Care Blood Loss
Slide 8: 134M+ Patient Market: The Untapped Potential for Blood Volume Analysis
134M+ Patient Market: The Untapped Potential for Blood Volume Analysis to Improve Outcomes and Healthcare Costs Heart Failure* ~7 million affected Hyponatremia® 3 to 6 million affected Hypertension* 120 million adults affected Blood Volume Derangement is Central to These Conditions Sepsis? 17 millio
Slide 9: The Heated Debate — What is the patient's volume status?
The Heated Debate — What is the patient’s volume status? £1 “Her hematocrit is very “| think he’s still a bit low. But she’s been “It might be time to wet; he needs to be getting lots of fluids. It’s pivot to anew diuresed.” not true anemia, it’s treatment plan.” dilutional.” HERO UNE CHEN
Slide 10: Optimal Blood Volume is Central to Effective Healthcare
Optimal Blood Volume is Central to Effective Healthcare Other volume assessment methods are inaccurate, costly, and invasive — often leading to suboptimal outcomes. Single BVA Blood Test HERO UNE CHEN
Slide 11: Solution & Technology
Solution & Technology
Slide 12: Capitalizing on the Next Generation of Care
Capitalizing on the Next Generation of Care Test results achievable within 30 minutes = Over 75,000+ Tests Shipped >95% Accurate Direct Measurement of Total Blood Volume, Plasma, & Red Cell Volume ‘Administered Over 170+ Peer-Reviewed Studies Confirming Blood Volume Measurement Leads to Better Outco
Slide 13: Over 75,000+ Tests Shipped to Leading U.S. Institutions
Over 75,000+ Tests Shipped to Leading U.S. Institutions, Demonstrating Widespread Utilization Allina Health ¥ aos HEATTH PLAN, MAYO CLINIC Gas mii NYU School of Medicine PRISMA THE QUEEN'S HEALTH. 3), MEDICAL CENTER Geisinger Health Plan W Main Line Health” WMC | Westchester VO Health Medical Center
Slide 14: New Game-Changing Daxor BVA Analyzer
New Game-Changing Daxor BVA™ Analyzer FDA-Cleared August 2025 Nasdaq Closing Bell Ceremony, August 8, 2025
Slide 15: A Technology Leap for Greater Patient Access
A Technology Leap for Greater Patient Access Leveraging 50 years of innovation and over 75,000 tests with our BVA-100™ device, we've developed the new BVA analyzer. This faster, easier, hand-held device - delivers precise blood volume data = making it accessible for use across both — hospital and am
Slide 16: Fast. Accurate. Easy.
Fast. Accurate. Easy. Inject Volumex®, Process Samples and Get Immediate Results A. @ injecting volumex @© sample Processing © evaresuits ‘HE BON WME CAPT
Slide 17: ezBVA Lab Service — No Capital Investment or Lab Work
ezBVA Lab Service — No Capital Investment or Lab Work mle Daxor’s novel CLIA certified facility provides on-demand, next day blood volume analysis results. Inject collect ship 1 Inject Volumex® 2 Collect blood samples 3 Ship to Daxor HERO UNE CHEN
Slide 18: Clinical & Health Economic Benefits
Clinical & Health Economic Benefits
Slide 19: Scientific Partnerships Fuel Our Market Leadership
Scientific Partnerships Fuel Our Market Leadership gh 3 2 ©) J ACC Karger YALE-NEW HAVEN en & JAC Failure Cardiorenal Medicine HosPITAL aM ee \NYUSchoo of Medicine (SIBAPTIST. W | Duketieaith q C F NYU LANGONE MEDICAL CENTER MEMORIAL HEALTH CARE @HFSA_—, OF fe THE UNIVERSITY OF anetican HEART FAILUR
Slide 20: Study Underscores BVA's Market Potential in Heart Failure
Study Underscores BVA’s Market Potential in Heart Failure Retrospective analysis in hospitalized heart failure patients n = 245, Mixed HFpEF/HFrEF Jb sex : dhe : then Reducing 30-day : Reducing 30-day : Reducing 1-year readmissions by p mortality by 82% + mortality by 86% 56% (P<0.001) q (P<0.001) :
Slide 21: BVA Drives Superior Outcomes and Value in Critical Care
BVA Drives Superior Outcomes and Value in Critical Care Every clinician understands the importance of maintaining normal blood volume, but the problem is how to measure it. The blood volume analyzer will mitigate the heated debate at the bedside. ~ Dr. Mihae Yu Blood Volume Measurements Improved ICU
Slide 22: Driving Exceptional Value in Healthcare
Driving Exceptional Value in Healthcare Blood Volume-Guided Treatment Extremely Cost Effective*® Retrospective analysis in hospitalized heart failure patients | n = 245, Mixed HFpEF/HFrEF 2.32 QALY Average Life-Extension i 5X More Cost- Effective Far below the threshold of $50,000 Per Patient Well a
Slide 23: Commercial Momentum
Commercial Momentum
Slide 24: Making a Difference in Multiple Medical Conditions
Making a Difference in Multiple Medical Conditions Patients With Critical Blood Volume Derangements in the U.S. Annually a * Heart Failure: 7M patients, 11M deaths, 1M annual hospitalizations Heart Failure Mes * Critical Care/Sepsis: 7.4 M admissions annually Critical Care * Broadening focus indicat
Slide 25: BVA Expansion Into High-Impact Outpatient Verticals
BVA Expansion Into High-Ilmpact Outpatient Verticals * Nephrology * Oncology Infusion Centers * Post-Surgical Follow-up Clinics * POTS & Dysautonomia Centers « Advanced Heart Failure Management Centers * Private Physician Office Labs HERO UNE CHEN
Slide 26: Vast, Untapped Market Potential
Vast, Untapped Market Potential Addressable Market — Annual Recurring Revenue {in millions) $7,000 $6,000 $5,790 $5,000 $4,000 $3,000 $2,027 nd $1,351 $1,000 | $2,695 ea =a Heart Failure Critical Care / Sepsis Hypertension Surgical Blood Loss & Transfusion Assumed at " - - hae 30% 20% 5% 10% For ill
Slide 27: Commercialization Channels
Commercialization Channels * Direct sales to medical centers and clinics for in/outpatient use * Sales & clinical support team of 12 ¢ International expansion with ISO 13485 certification ¢ Military contract awards * Partnerships with MedAxiom, an ACC Company, Heart Failure Society of America y MEDA
Slide 28: Strategy & Conclusion
DAXOR BVA-100 Strategy & Conclusion
Slide 29: Executive Summary
Executive Summary Strong Growth & Strategic Wins + Revenue increased 73% in H1 2025 year-over-year (unaudited), signaling strong market adoption + Realized a 47.0% Volumex price increase, demonstrating the industry's willingness to pay for precision diagnostics + Expanded our reach by signing 17 new
Slide 30: Managing for Growth
Managing for Growth I Vertical integration of Melleatee Advancing diagnostic Institutionalizing Next generation device and Megatope® from + a Pi é - & therapeutic adoption with usage < © BD eel ore AVE 2022) Paper aon ate strategic alliances protocols & treatment sg guidance of diagnostics _ TT Expa
Slide 31: Patent, Research & Development Activity
Patent, Research & Development Activity 20,000 SF US Patents Awarded Research Facility Equipped with State-of-the- Art Level 4 Clean Rooms Patents Pending New Patents Anticipated for 2026 New Patents Filed 2023 HERO UNE CHEN
Slide 32: $7M+ Government Grants for Next-Gen Systems
S7M+ Government Grants for Next-Gen Systems * Simple, fast, hand-held blood volume analyzer 510(k)-cleared for military and civilian use * Novel patent-pending fluorescent tracer development * BVA integration into Electronic Health Records * Clinical decision support tools for fluid management in he
Slide 33: Senior Leadership
Senior Leadership o2@ Michael Jonathan John L. Robert Kathryn A. i Linda Noa Kohl, Feldschuh, Feldschuh, Jefferies, Michel, Kornafel, Cooper, MDS, MBA President & Chief Scientific MD, MBA, CPA, MBA MT (ASCP) VP Development wejGrante ss Chief Executive Officer MPH, FAC, Chief Financial} Sr. VP Market
Slide 34: Key Metrics
Key Metrics 1940 Act Reporting Company | OPrice History ator Corp. (OXR) 13,68 Publicly Traded Since 1971 Stock Symbol: DXR Exchange’ Nasdaq Recent Price: $13.68 (2/0 01/6/2026) 52 Week Range: $6.55 to $14.76 Market Cap: $69.2M (2/0 01/06/2025) Shares Outstanding: 5.06M {2/0 01/06/2025) Free Float:
Slide 35: Highlights
Highlights Broad and deep IP portfolio with patented 510(k) clearance for next-generation blood volume technology analyzer, results within 30 minutes Awarded new patent for blood volume guidance Over 75,000+ tests shipped with 170+ peer-reviewed technology to improve treatment & outcomes published s
Slide 36: References
References 1. Economic Issues in Heart Failure in the United States 2. Intelligent Intensive Care Unit 3. Sepsis Alliance 4. Health Care Expenditures and Use Associated with Hypertension Among U.S. Adults 5. Transfusion Transmitted Disease 6. The Prevalence of Hyponatremia in the U.S oe American Soc
Slide 37: Daxor
DAXOR THE BLOOD VOLUME COMPANY” 107 Meco Lane, Oak Ridge, TN 37830 1865.425-0555 | Info@daxor.com Daxor.com